{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:08:32Z","timestamp":1791983312323,"version":"4.4.0"},"reference-count":75,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,14]]},"DOI":"10.14797\/mdcvj.1066","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T09:01:05Z","timestamp":1647248465000},"page":"17-26","source":"Crossref","is-referenced-by-count":88,"title":["ATTR Epidemiology, Genetics, and Prognostic Factors"],"prefix":"10.14797","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-1614","authenticated-orcid":false,"given":"Chukwuemeka A.","family":"Obi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7001-3956","authenticated-orcid":false,"given":"William C.","family":"Mostertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-7464","authenticated-orcid":false,"given":"Jan M.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-0248","authenticated-orcid":false,"given":"Daniel P.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"10038","key":"key20220314090100_B1","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"key20220314090100_B2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","year":"2019","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"key20220314090100_B3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ane.13035","article-title":"Hereditary transthyretin-related amyloidosis","volume":"139","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"key20220314090100_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.07.022","article-title":"Cardiac amyloidosis: An underdiagnosed\/underappreciated disease","volume":"67","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"6","key":"key20220314090100_B5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","year":"2019","journal-title":"ESC Heart Fail"},{"issue":"1","key":"key20220314090100_B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS \u2013 The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"key20220314090100_B7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2019.12.033","article-title":"The Alzheimer\u2019s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease: JACC Focus Seminar","volume":"75","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20220314090100_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis","volume":"5","year":"2016","journal-title":"Neurol Ther"},{"issue":"14","key":"key20220314090100_B9","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis","volume":"135","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"key20220314090100_B10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"8","key":"key20220314090100_B11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejim.2013.10.007","article-title":"Systemic amyloidoses: what an internist should know","volume":"24","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"2","key":"key20220314090100_B12","article-title":"Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden","volume":"8","year":"2021","journal-title":"Open Heart"},{"key":"key20220314090100_B13","first-page":"7","article-title":"Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"10","key":"key20220314090100_B14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20220314090100_B15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"38","key":"key20220314090100_B16","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"key20220314090100_B17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cardfail.2017.12.005","article-title":"Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis","volume":"24","year":"2018","journal-title":"J Card Fail"},{"issue":"3","key":"key20220314090100_B18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","year":"2008","journal-title":"Ann Med"},{"issue":"9","key":"key20220314090100_B19","first-page":"e139","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"key20220314090100_B20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"10","key":"key20220314090100_B21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of Heart Failure: A Contemporary Perspective","volume":"128","year":"2021","journal-title":"Circ Res"},{"issue":"10","key":"key20220314090100_B22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"key20220314090100_B23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1073\/pnas.81.3.694","article-title":"Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin","volume":"81","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"key20220314090100_B24","doi-asserted-by":"crossref","first-page":"12224","DOI":"10.1016\/S0021-9258(17)39013-0","article-title":"Structure of the human prealbumin gene","volume":"260","year":"1985","journal-title":"J Biol Chem"},{"issue":"1","key":"key20220314090100_B25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","year":"2019","journal-title":"Amyloid"},{"issue":"sup1","key":"key20220314090100_B26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/13506129.2019.1582484","article-title":"Positive family history decreases diagnosis time by over 200","volume":"26","year":"2019","journal-title":"Amyloid"},{"issue":"2","key":"key20220314090100_B27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20220314090100_B28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","year":"2015","journal-title":"Amyloid"},{"issue":"4","key":"key20220314090100_B29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506129.2019.1634539","article-title":"Founder effect of the Glu89Gln TTR mutation in the Bulgarian population","volume":"26","year":"2019","journal-title":"Amyloid"},{"key":"key20220314090100_B30","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","year":"2019","journal-title":"Eur Heart J"},{"issue":"9","key":"key20220314090100_B31","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"key20220314090100_B32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study","volume":"59","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"key20220314090100_B33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","year":"2017","journal-title":"Genet Med"},{"key":"key20220314090100_B34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"key20220314090100_B35","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/archneur.56.9.1152","article-title":"Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64","volume":"56","year":"1999","journal-title":"Arch Neurol"},{"issue":"5","key":"key20220314090100_B36","article-title":"Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program","volume":"14","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"Suppl 1(Suppl 1)","key":"key20220314090100_B37","first-page":"S3","article-title":"European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"key20220314090100_B38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/13506120903093944","article-title":"Parent-of-origin effect in transthyretin related amyloid polyneuropathy","volume":"16","year":"2009","journal-title":"Amyloid"},{"issue":"3","key":"key20220314090100_B39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cjca.2019.12.033","article-title":"Amyloidosis as a Systemic Disease in Context","volume":"36","year":"2020","journal-title":"Can J Cardiol"},{"issue":"9","key":"key20220314090100_B40","first-page":"1954","article-title":"Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies","volume":"10","year":"2021"},{"issue":"7 Suppl","key":"key20220314090100_B41","first-page":"S107","article-title":"Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges","volume":"23","year":"2017","journal-title":"Am J Manag Care"},{"issue":"3","key":"key20220314090100_B42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"key20220314090100_B43","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"issue":"11","key":"key20220314090100_B44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","article-title":"Cardiac amyloidosis: the need for early diagnosis","volume":"27","year":"2019","journal-title":"Neth Heart J"},{"key":"key20220314090100_B45","volume-title":"Cardiovascular Disease in Racial and Ethnic Minority Populations","year":"2021"},{"issue":"3","key":"key20220314090100_B46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/CND.0000000000000270","article-title":"Hereditary Transthyretin Amyloidosis: Clinical Presentation and Management Updates","volume":"21","year":"2020","journal-title":"J Clin Neuromuscul Dis"},{"key":"key20220314090100_B47","article-title":"Hereditary transthyretin amyloidosis overview","year":"2020","journal-title":"Neurol Sci"},{"issue":"5","key":"key20220314090100_B48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmg.31.5.351","article-title":"Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate","volume":"31","year":"1994","journal-title":"J Med Genet"},{"issue":"3","key":"key20220314090100_B49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","year":"2008","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"key20220314090100_B50","first-page":"71","article-title":"Clinical features of TTR-FAP in Portugal","volume":"19","year":"2012","journal-title":"Amyloid"},{"issue":"7","key":"key20220314090100_B51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"key20220314090100_B52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.ejhg.5201095","article-title":"Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden","volume":"12","year":"2004","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"key20220314090100_B53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/13506120701815373","article-title":"Gender-related risk of myocardial involvement in systemic amyloidosis","volume":"15","year":"2008","journal-title":"Amyloid"},{"key":"key20220314090100_B54","unstructured":"Liang D. The potency of AG10 in stabilizing transthyretin is driven by interactions mimicking the disease-suppressing T119M variant [dissertation]. Stockton, California: University of the Pacific; 2019. 57 p."},{"issue":"5539","key":"key20220314090100_B55","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","year":"2001","journal-title":"Science"},{"issue":"30","key":"key20220314090100_B56","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"key20220314090100_B57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis","volume":"2","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"11","key":"key20220314090100_B58","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-Type Natriuretic Peptide During Treatment With Sacubitril\/Valsartan: The PARADIGM-HF Trial","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20220314090100_B59","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"key20220314090100_B60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"key20220314090100_B61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","article-title":"Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis","volume":"22","year":"2015","journal-title":"Amyloid"},{"issue":"11","key":"key20220314090100_B62","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"key20220314090100_B63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","year":"2019","journal-title":"Amyloid"},{"issue":"3","key":"key20220314090100_B64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","year":"2015","journal-title":"Amyloid"},{"issue":"5","key":"key20220314090100_B65","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"21","key":"key20220314090100_B66","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"key20220314090100_B67","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20220314090100_B68","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis","volume":"5","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"key20220314090100_B69","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"14","key":"key20220314090100_B70","article-title":"Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis","volume":"9","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"key20220314090100_B71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of Arrhythmias in Cardiac Amyloidosis","volume":"6","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"key20220314090100_B72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis","volume":"140","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"key20220314090100_B73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"key20220314090100_B74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"key20220314090100_B75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T09:01:53Z","timestamp":1647248513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1066\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,14]]}},"alternative-id":["10.14797\/mdcvj.1066"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1066","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}